Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Conditions
Interventions
Cemiplimab
ISA101b
Locations
26
United States
Arizona Oncology Associates
Tucson, Arizona, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Regeneron Research Site
Orange, California, United States
Universitair Ziekenhuis Gent
Ghent, East Flanders, Belgium
UZ Leuven
Leuven, Vlaams Brabant, Belgium
CHIREC Delta Hospital / Chirec Cancer Institute
Brussels, Belgium
Start Date
June 28, 2021
Primary Completion Date
May 22, 2023
Completion Date
May 29, 2024
Last Updated
September 8, 2025
NCT06157151
NCT06952660
NCT04895709
NCT05108298
NCT05952141
NCT07276360
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions